Opinion|Videos|August 8, 2024
Esketamine for TRD: MOA, Application, and Adverse Events
Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.
Advertisement
Advertisement
Related to this article
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
2
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
3
ESSENCE: Semaglutide Improves Liver Markers in MASH Without Obesity
4
Elebsiran Plus Tobevibart Suppresses HDV RNA in Phase 3 ECLIPSE 1 Trial
5